Erdem Ak

Erdem Ak

Auto-generated profile, based on publicly available information

Erdem Ak

Department of Pediatrics, Pediatric Hematology and Oncology, Faculty of Medicine, Mersin University, Mersin, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2018 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
ADAli Duyu
Ali Duyu
EÇElvan Çağlar Çıtak
Elvan Çağlar Çıtak
EAErdem Ak
Erdem Ak
SKSerhan Kupeli
Serhan Kupeli
BYBegül Yağcı
Begül Yağcı
KSKerem Sezer
Kerem Sezer
Objective: In this study, we evaluated the frequency of euthyroid sick syndrome (ESS) among patients with childhood cancer and its association with the stage of disease, nutritional parameters and cytokines levels. Methods: Eighty newly diagnosed children were included in the study. ESS was assessed in two different ways. According to criteria 1 ESS was present if free triiodothyronine (fT3) was below the lower limit and free thyroxine was within the normal or low limits, thyroid-stimulating hormone (TSH) was in the normal range. According to criteria 2, in addition to the above, it was required that reverse triiodothyronine (rT3) be performed and was higher than normal limits. Results: Three of our pediatric patients had subclinical hypothyroidism and two had subclinical hyperthyroidism. Out of 75 patients, ESS was identified in 14 (17.3%) according to criteria 1 and in eight (10.6%) according to criteria 2. Only fT3 levels were significantly different in the ESS (+) and ESS (-) groups (p < 0.05) according to criteria 1. A significantly negative correlation between interleukin (IL)6 and fT3 was found, according to both sets of criteria. tumor necrosis factor alpha was negatively correlated with fT3 levels only in the criteria 1 group. There were no correlations between IL-1 beta and fT3, free thyroxine, rT3 and TSH levels. Conclusion: ESS may occur in childhood cancer and thyroid function testing should be performed routinely when cancer is diagnosed.

3 May 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
STSelçuk Teke
Selçuk Teke
GBGülsen Bayrak
Gülsen Bayrak
EAErdem Ak
Erdem Ak
AKAli Can Korkmaz
Ali Can Korkmaz
SYsakir necat yilmaz
sakir necat yilmaz
ADAli Delibaş
Ali Delibaş
Cisplatin is widely used in pediatric oncology but is limited by its dose-dependent nephrotoxicity. The renin–angiotensin–aldosterone system (RAAS) has been implicated in cisplatin-induced renal injury. Losartan, an angiotensin II receptor blocker, may offer renal protection; however, its effects on apoptosis and regeneration in this context remain unclear. This study aimed to investigate the potential protective role of losartan against cisplatin-induced nephrotoxicity, specifically by assessing its impact on apoptosis and tubular regeneration. Fifteen female BALB/c mice were randomly assigned to three groups ( n = 5 per group): Control, cisplatin (12.7 mg/kg, i.p., single dose), and cisplatin + losartan (10 mg/kg/day, oral). Losartan was administered for nine consecutive days, starting 4 days before cisplatin exposure. Histopathological examination, active caspase-3 immunostaining (for apoptosis), and 5-bromo-2-deoxyuridine (BrdU) labeling (for cell proliferation) were performed. Glomerular and tubular injury scores, caspase-3 H-scores, and BrdU-positive cell counts were statistically analyzed using the Kruskal–Wallis H and Mann–Whitney U tests. Cisplatin significantly increased glomerular ( p = 0.006, p = 0.005, p = 0.006) and tubular injury scores ( p = 0.008, p = 0.007, p = 0.007, p = 0.007, p = 0.007), elevated active caspase-3 expression ( p = 0.002), and reduced BrdU-positive cell counts ( p = 0.009) compared to control. Losartan co-treatment significantly reduced glomerular ( p = 0.008, p = 0.005, p = 0.008) and tubular injury ( p = 0.008, p = 0.008, p = 0.009, p = 0.008, v) and decreased caspase-3 expression ( p = 0.009). Additionally, BrdU-positive cell counts were significantly higher in the cisplatin + losartan group compared to both control and cisplatin groups ( p = 0.009), indicating enhanced regeneration. Losartan mitigates cisplatin-induced nephrotoxicity by suppressing apoptosis and promoting tubular regeneration. These findings support the potential therapeutic role of RAAS inhibition in preventing cisplatin-associated renal injury.